Abstract:Antibiotics resistance in Helicobacter pylori (H. pylori) is the major factor for eradication failure. Molecular tests including fluorescence in situ hybridization, PCR-restriction fragment length polymorphism, and dual priming oligonucleotide-PCR (DPO-PCR) play critical roles in the detection of antibiotic susceptibility; however, limited knowledge is known about application of multiple genetic analysis system (MGAS) in the area of H. pylori identification and antibiotics resistance detection.The aim of this study is to determine the antibiotics resistance using different molecular tests and evaluate the treatment outcomes of E-test-based genotypic resistance.A total of 297 patients with dyspepsia complaint were recruited for gastroscopies. Ninety patients with H. pylori culture positive were randomly divided into 2 groups (test group and control group). E-test, general PCR, and MGAS assay were performed in test group. Patients in control group were treated with empirical therapy (rabeprazole + bismuth potassium citrate + amoxicillin [AMX] + clarithromycin [CLR]), whereas patients in test group received quadruple therapy based on E-test results twice daily for 14 consecutive days. The eradication effect of H. pylori was confirmed by C-urea breath test after at least 4 weeks when treatment was finished.Rapid urease test showed 46.5% (128/297) patients with H. pylori infection, whereas 30.3% (90/297) patients were H. pylori culture positive. E-test showed that H. pylori primary resistance rate to CLR, AMX, metronidazole, tetracycline, and levofloxacin (LVX) was 40.0% (18/45), 4.4% (2/45), 53.3% (24/45), 0% (0/45), and 55.6% (25/45), respectively. In addition, there are many multidrug resistant (MDR) phenotypes, and the MDR strains have higher minimum inhibitory concentration than their single-drug resistant counterparts. Considering E-test as the reference test, the sensitivities of general PCR and MGAS in detecting CLR resistance were 83.3% (15/18) and 94.4% (17/18), whereas in detecting LVX resistance were 100% (25/25) and 83.3% (15/18), respectively. Finally, the eradication rate in test group was significantly higher than that in control group as demonstrated by intention-to-treat analysis and per-protocol analysis.MGAS is a promising assay for H. pylori identification and antibiotic susceptibility testing. Phenotypic resistance-guided quadruple therapy showed a high efficacy in treating patients with H. pylori infection.

The Eradication Efficacies Of Hybrid Therapy As First-Line Regimen Plus Levofloxacin-Containing Triple Therapy As Second-Line Regimen For Helicobacter Pylori Infection

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Comparison of the Detection of Helicobacter Pylori Infection by Commercially Available Serological Testing Kits and the 13C-Urea Breath Test.

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Evaluation of Multiplex ARMS-PCR for Detection Ofhelicobacter Pylorimutations Conferring Resistance to Clarithromycin and Levofloxacin

Comparative Study on Eradication Therapy of 1 440 Newly Diagnosed Patients with Helicobacter Pylori Infection

Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance

Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.

Identifying the Best Regimen for Primary Eradication of Helicobacter Pylori: Analysis of 240 Cases.

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Efficacy of Tetracycline-containing Triple Therapy for Eradication of Helicobacter pylori Infection

Hybrid Therapy Regimen for Helicobacter Pylori Eradication

High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter Pylori and High Eradication Rate with Phenotypic Resistance-Guided Quadruple Therapy.

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen – An open-label, randomized trial

Susceptibility-guided Vs. Empirical 10-Day Quadruple Treatment for Helicobacter Pylori-Infected Patients: A Prospective Clinical Trial of First-Line Therapy